Biomarck initiates Phase 2 Clinical study for NSCLC
Biomarck Pharmaceuticals affirmed initiation of Phase 2 Clinical study in advanced NSCLC. The study is meant to compare standard of Care Therapy alone to SOC plus BIO-11006. BIO-11006…
Read More...
Read More...
